Education
About Us
Working with TipRanks
Follow Us
Indivior PLC (INDV)
NASDAQ:INDV
INDV Stock Chart & Stats
$31.20
--
Market closed
$31.20
--
Day’s Range― - ―
52-Week Range$7.62 - $32.14
Previous CloseN/A
VolumeN/A
Average Volume (3M)2.06M
Market Cap
$4.00B
Enterprise Value$3.02B
Total Cash (Recent Filing)$445.00M
Total Debt (Recent Filing)$52.00M
Price to Earnings (P/E)31.9
Beta0.62
Next Earnings
Feb 12, 2026EPS Estimate
0.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.72
Shares Outstanding124,853,900
10 Day Avg. Volume3,013,236
30 Day Avg. Volume2,059,888
Financial Highlights & Ratios
PEG Ratio239.55
Price to Book (P/B)-4.71
Price to Sales (P/S)1.38
P/FCF Ratio234.39
Enterprise Value/Market Cap0.76
Enterprise Value/Revenue2.56
Enterprise Value/Gross Profit3.18
Enterprise Value/Ebitda10.31
Forecast
1Y Price Target
$37.00Price Target Upside18.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial PerformanceINDV reported a strong third quarter that exceeded expectations across all key metrics and validated the positive call on the stock.
Market PositionINDV has a unique position to expand the penetration of long-acting injectables in the treatment of opioid use disorder.
Stock ValuationINDV stock has outperformed in 2025 (+101.9% vs 23.2% XBI), but the stock remains fundamentally undervalued.
Bears Say
Indivior News
INDV FAQ
What was Indivior PLC’s price range in the past 12 months?
Indivior PLC lowest stock price was $7.62 and its highest was $32.14 in the past 12 months.
What is Indivior PLC’s market cap?
Indivior PLC’s market cap is $4.00B.
When is Indivior PLC’s upcoming earnings report date?
Indivior PLC’s upcoming earnings report date is Feb 12, 2026 which is in 98 days.
How were Indivior PLC’s earnings last quarter?
Indivior PLC released its earnings results on Oct 30, 2025. The company reported $0.72 earnings per share for the quarter, beating the consensus estimate of $0.412 by $0.308.
Is Indivior PLC overvalued?
According to Wall Street analysts Indivior PLC’s price is currently Undervalued.
Does Indivior PLC pay dividends?
Indivior PLC does not currently pay dividends.
What is Indivior PLC’s EPS estimate?
Indivior PLC’s EPS estimate is 0.68.
How many shares outstanding does Indivior PLC have?
Indivior PLC has 124,853,900 shares outstanding.
What happened to Indivior PLC’s price movement after its last earnings report?
Indivior PLC reported an EPS of $0.72 in its last earnings report, beating expectations of $0.412. Following the earnings report the stock price went up 15.412%.
Which hedge fund is a major shareholder of Indivior PLC?
Currently, no hedge funds are holding shares in INDV
Indivior Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$37.00 (18.59% Upside)
$37.00 (18.59% Upside)
Blogger Sentiment
Bullish
INDV Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 75.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 8.4%
Last 30 Days ▲ 66.0%
Last 30 Days ▲ 66.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
248.58%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-3.28%
Trailing 12-Months
Company Description
Indivior PLC
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
INDV Company Deck
INDV Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a generally optimistic outlook with strong performance and growth in SUBLOCADE, raised financial guidance, and significant cost-saving initiatives. However, organizational restructuring costs and challenges in expanding the LAI market were noted as concerns.View all INDV earnings summariesINDV Stock 12 Month Forecast
Average Price Target
$37.00
▲(18.59% Upside)
Technical Analysis
Pacira Pharmaceuticals
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Evotec AG
―
Ownership Overview
4.95% Insiders
4.10% Mutual Funds
0.30% Other Institutional Investors
83.57% Public Companies and
Individual Investors